Elonva (corifollitropin alfa)
- Region
- 🇪🇺 EU
- Active substance
- corifollitropin alfa
- Company
- Organon N.V.
- Status
- Authorised
- Therapeutic area
- Reproductive Techniques, Assisted; Ovulation Induction; Investigative Techniques
- CHMP opinion
- Thu 19 Nov 2009
- EU approval
- Mon 25 Jan 2010
- Application
- EMEA/H/C/001106
- ATC
- G03GA09
- Official record
- www.ema.europa.eu
Indication
Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG).
Regulatory milestones
No milestones recorded in the last year.
Follow Elonva
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.